NSE: HCG | BSE: 539787

Await Turnaround

Download real time

619.25 -10.20 (-1.62%)

53.01% Gain from 52W Low

102.5K NSE+BSE Volume

NSE 30 Sep, 2025 10:26 AM (IST)

8,731.4

Market Cap

Above industry Median

0.6

Beta 1Year

Very Low volatility

Healthcare Global Enterprises Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for HCG, BSE:539787 Healthcare Global Enterprises Ltd.

Search Inside the pdf :

Healthcare Global Enterprises Ltd.

29 Aug 2025, 12:00AM

619.25

-1.62%

HEALTHCARE GLOBAL ENTERPRISES LIMITED

Hold: Healthcare Global Enterpri...

Target

Geojit BNP Paribas

HCG is poised to deliver strong top-line growth over the next 23 years, supported by improvements in ARPOB and ongoing bed additions. However, profitability recovery may be gradual given the debt-funded nature of recent capex. Management has indicated plans for a capital infusion, which could help ease the interest burden. With KKR as the new promoter, the business is expected to undergo transformation, enhancing growth and operational efficiencies. Considering the elevated debt levels, we retain our Hold...

Promoters have decreased holdings from 71.22% to 62.46% in Jun 2025 qtr

Healthcare Global Enterprises Ltd.

05 Aug 2025

619.25

-1.62%

Result Update:Health.Global

Buy: Healthcare Global Enterpri...

Target

Axis Direct

We maintain our BUY recommendation on the stock.

Healthcare Global Enterprises Ltd. is trading above its 200 day SMA of 559.8

Healthcare Global Enterprises Ltd.

05 Aug 2025

619.25

-1.62%

Decent quarter, occupancy may have hit a trough

Hold: Healthcare Global Enterpri...

Target

ICICI Securities Limited

HealthCare Global Enterprises’ (HCG) Q1FY26 result was in line with our expectations. Revenue grew 16.7% YoY driven by new centres in Mumbai (+28% YoY), Kolkata (+17% YoY) and Ahmedabad (+22% YoY) while key cluster of Karnataka and East India grew at a moderate pace.

Healthcare Global Enterprises Ltd. is trading below its 30 day SMA of 672.7

Healthcare Global Enterprises Ltd.

28 Jun 2025

619.25

-1.62%

Pick of the Week:Health.Global

Buy: Healthcare Global Enterpri...

Target

Axis Direct

We recommend a BUY with TP of Rs 600, implying an upside of 10% from the CMP.

Healthcare Global Enterprises Ltd. has gained 44.80% in the last 1 Year

Healthcare Global Enterprises Ltd.

27 May 2025

619.25

-1.62%

Result Update:Health.Global

Buy: Healthcare Global Enterpri...

Target

Axis Direct

We maintain our BUY recommendation on the stock.

Healthcare Global Enterprises Ltd.'s price crossed below 50Day SMA today

Healthcare Global Enterprises Ltd.

27 May 2025

619.25

-1.62%

HealthCare Global Enterprises (HCG IN) Q4FY25 Result Update ...

Buy: Healthcare Global Enterpri...

Target

Prabhudas Lilladhar

HealthCare Global Enterprises' (HCG) Q4 consolidated EBITDA grew by 15% YoY to Rs1.1bn; in line with our estimate. The company's asset-light approach with a focus on partnerships has made its business model more capital efficient and scalable, in our view. We believe the strategic investment by KKR will bring in more operational and financial efficiency. Currently, HCG enjoys 13-14% pre IND AS margin, which is lower than its peers. We expect KKR to drive growth through bed expansion, rationalization of existing assets and scale up of...

Promoters pledged 0.71% of shares in last quarter. Total pledge stands at 5.70% of promoter holdings

Healthcare Global Enterprises Ltd.

21 Apr 2025

619.25

-1.62%

HEALTHCARE GLOBAL ENTERPRISES LIMITED

Hold: Healthcare Global Enterpri...

Target

Geojit BNP Paribas

Healthcare Global Enterprises Ltd.'s price crossed below 50Day SMA today

Healthcare Global Enterprises Ltd.

28 Feb 2025

619.25

-1.62%

Result Update:Health.Global

Buy: Healthcare Global Enterpri...

Axis Direct

We maintain our BUY recommendation on the stock.

Healthcare Global Enterprises Ltd. is trading above its 200 day SMA of 559.8

Healthcare Global Enterprises Ltd.

28 Feb 2025

619.25

-1.62%

HealthCare Global Enterprises (HCG IN) Event Update Ownership...

Buy: Healthcare Global Enterpri...

Target

Prabhudas Lilladhar

With 51% stake in HCG, KKR has become the largest shareholder. We believe the strategic investment by KKR will bring in more operational and financial efficiency. Currently, HCG enjoys 15% pre IND AS margin, which is lower than its peers. We expect KKR to drive growth through bed expansion, rationalization of existing assets and scale up of margins. The company's asset-light approach with a focus on partnerships has made its business model more capital efficient and scalable, in our view. Our FY26/FY27E EBITDA stands...

Promoters pledged 0.71% of shares in last quarter. Total pledge stands at 5.70% of promoter holdings

Healthcare Global Enterprises Ltd.

25 Feb 2025

619.25

-1.62%

PE change of hands to improve prospects

Hold: Healthcare Global Enterpri...

Target

ICICI Securities Limited

HealthCare Global Enterprises’ (HCG) current promoter CVC Capital (Aseco PTE) is likely to sell up to 54% of its stake in the company to another private equity (PE) firm, KKR, at an agreed price of INR 445/share (cumulative value between INR 320bn–339bn).

Promoters pledged 0.71% of shares in last quarter. Total pledge stands at 5.70% of promoter holdings

Is Healthcare Global Enterprises Ltd. worth buying?

46 Votes:

Buy 73.91%

Sell 13.04%

Hold 13.04%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf